JS Link, Inc.

Based in South Korea, JS Link, Inc. specializes in biotechnology and permanent magnet technology, offering advanced genomic sequencing services and producing rare earth magnets for diverse industrial applications. JS Link, Inc. operates in the biotechnology and permanent magnet sectors, providing genomic sequencing services and rare earth magnets, respectively.

The company is headquartered in Seoul, South Korea. It was involved in a PIPE funding round on December 23, 2011, raising KRW 10,000 million, with Atinum Investment participating. This amount matches the total amount raised by the company to date, indicating significant investor confidence. The company has engaged in a total of 4 deals since its inception.

JS Link, Inc. specializes in two primary business sectors: biotechnology and permanent magnet technology. The biotechnology division offers a comprehensive suite of genomic sequencing services, including Whole Genome Sequencing, De Novo Sequencing, and targeted sequencing methodologies such as Whole Exome and Transcriptome Sequencing. These services cater to complex biological research needs, facilitating advancements in personalized medicine and health diagnostics.

The permanent magnet division produces rare earth magnets, pivotal in numerous applications, ranging from industrial machinery to consumer electronics. JS Link serves a diverse clientele including research institutions, healthcare providers, and manufacturing companies primarily located in Asia, Europe, and North America. JS Link, Inc. generates revenue through a structured transaction model that includes direct sales of its biotechnology services and permanent magnet products to business clients and research institutions.

Client engagements are typically structured as project-based contracts, where organizations commission specific genomic analyses or bulk purchases of magnets based on their operational needs. The pricing for these services and products varies according to complexity and volume, catering to both high-throughput research laboratories and smaller-scale users. The flagship offerings, particularly in the biotechnology sector, may involve premium pricing due to their advanced technology use, ensuring high-quality results that align with client expectations in sectors such as healthcare and industrial applications. In December 2011, JS Link, Inc.

raised KRW 5. 07 billion in an IPO, selling 658,418 shares at KRW 7,700 apiece, above the expected KRW 6,000-7,000 price range on the KOSDAQ. The company plans to leverage this funding to enhance its product development capabilities in both biotechnology and permanent magnet sectors. Future initiatives include the launch of new genomic sequencing services aimed at improving efficiency and accuracy in biological research.

Additionally, JS Link is targeting expansion into European markets by 2025, aiming to establish partnerships with local healthcare and research institutions.